Our Story
The story of Xtagen™ began in Australia, more than 16 years ago, where a breakthrough marine peptide complex — now known as Abagen™ — was discovered through pioneering research led by Dr. Simone Osborne of CSIRO, in collaboration with Southern Ocean Biotech.
The research focused on the therapeutic potential of abalone-derived peptides, revealing their remarkable ability to modulate inflammation, oxidative stress, and vascular responses at a molecular level.
A Scientific Breakthrough
Following years of intensive investigation, the innovation was granted International Patent WO 2017/124149 in 2017. Abagen™ is now developed and manufactured by Southern Ocean Biotech, a marine biotechnology company based in Portland, Australia that specializes in the extraction and stabilization of high-value bioactive compounds from marine sources.
Xania Corporation : Taking Science Global
XTAGEN™, built around Abagen™ as its core ingredient, is manufactured according to the stringent quality, safety, and efficacy standards mandated by Australian regulatory authorities. Every batch is produced under tightly controlled conditions to ensure consistency, scientific integrity, and clinical alignment.
To take this breakthrough from the lab to the world, Xania Corporation USA Inc, a global healthcare group, has joined hands with Southern Ocean Biotech in an institutional partnership. With a strong footprint across the United States, Australia, United Arab Emirates, India, and commercial activities spanning Asia, Africa, Europe, and the Gulf, Xania specialises in the formulation, regulatory strategy, and global distribution of high-quality pharmaceutical and nutraceutical products.
XTAGEN™ Not Just a Product
Today, XTAGEN™ stands as a symbol of what’s possible when deep science meets visionary execution. It is not just a product — it’s a reflection of global collaboration, long-term dedication, and a shared mission to deliver meaningful health solutions across borders.
